SOURCE-LINKED STUDY SUMMARY
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Abstract summarizedQuality not appraised
- What was studied
- Randomized, double-blind trial of tesamorelin for liver fat in HIV-associated NAFLD; primary endpoint was hepatic fat fraction (HFF).
- Who / model studied
- 61 enrolled with HIV and HFF ≥5%; 30 received tesamorelin and 30 placebo.
- Studied dose & schedule
- Tesamorelin 2 mg daily versus placebo for 12 months, followed by a 6-month open-label phase.
- What the study found
- HFF reduction versus placebo: 4·1 percentage points (95% CI 0·7–7·6), or 37% relative reduction. HFF fell below 5% in 35% versus 4%. Glucose outcomes did not differ; localized injection complaints were more frequent, none serious.
- Limitations & context
- Abstract assessment. Findings concern HIV-associated NAFLD; long-term liver histology effects remain uncertain.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s2352-3018(19)30338-8